- Record: found
- Abstract: found
- Article: not found
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
José A Martínez-Piñeiro
1 ,
Luis Martínez-Piñeiro ,
Eduardo Solsona ,
Rafael Hernández Rodríguez ,
Jesús María Fernández Gómez ,
Marcelino González Martín ,
Jesús Rodríguez Molina ,
Anabel Gimeno Collado ,
Nicolás Flores ,
Santiago Isorna ,
Carlos Pertusa ,
Mariano Rabadán ,
Ander Astobieta ,
José Emilio Camacho ,
Salvador Arribas ,
Rosario Madero
Oct 2005
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We determined if a third of the dose of intravesical bacillus Calmette-Guerin (BCG) has the same efficacy than a standard dose for decreasing the risk of recurrence and progression after transurethral resection in patients with superficial high risk (stages T1G3 and carcinoma in situ) bladder cancer. Also, we evaluated toxic side effects.